...
首页> 外文期刊>European journal of clinical pharmacology >Effects of CYP2C19, MDR1, and interleukin 1-B gene variants on the eradication rate of Helicobacter pylori infection by triple therapy with pantoprazole, amoxicillin, and metronidazole.
【24h】

Effects of CYP2C19, MDR1, and interleukin 1-B gene variants on the eradication rate of Helicobacter pylori infection by triple therapy with pantoprazole, amoxicillin, and metronidazole.

机译:CYP2C19,MDR1和白介素1-B基因变异对通过潘托拉唑,阿莫西林和甲硝唑三联疗法根除幽门螺杆菌感染的影响。

获取原文
获取原文并翻译 | 示例

摘要

OBJECTIVE: Eradication of H. pylori is an important treatment strategy in peptic ulcer patients. Current regimens of eradication consist of proton pump inhibitor (PPI) and two antibiotics. Effects of PPI may depend on their metabolism, and other factors important for the pathophysiology of peptic ulcer disease. Aim of the present study was to evaluate an association of CYP2C19, MDR1, and IL-1B polymorphisms with the eradication rate of H. pylori in Polish Caucasian patients treated with a triple therapy of pantoprazole, amoxicillin, and metronidazole. METHODS: A total of 139 peptic ulcer patients, positive for H. pylori infection, were treated with triple therapy (pantoprazole + amoxicillin + metronidazole). Subsequently, the patients were divided into two groups (group 1, success, and group 2, failure of eradication after therapy) and genotyped by the PCR-RFLP method for the presence of CYP2C19 variant alleles (*2, *3, and *17), and MDR1 3435C>T and IL-1B +3954C>T polymorphisms. Pantoprazole serum concentrations were measured using the HPLC method. RESULTS: No significant differences in frequency or distribution of CYP2C19 genotypes were found between the two groups of patients (i.e., with successful H. pylori eradication and treatment failure). However, any carrier of defective CYP2C19*2/*2 genotype was found among patients with treatment failure. Similarly, MDR1 and IL-1B genotypes were found to be significantly associated with the success or failure of H. pylori eradication. Univariate and multivariate analysis of the genotypes did not reveal any significant association between the genotypes and H. pylori eradication. Pantoprazole concentrations differed significantly, and were the highest in patients with defective allele CYP2C19*2 carriers and lowest in hyperactive genotype homozygotes CYP2C19*17/*17. CONCLUSION: The results suggest that the CYP2C19 genotype contrary to MDR1 and IL-1B genotypes may have an impact on the efficacy of H. pylori eradication in peptic ulcer patients treated with pantoprazole in Polish Caucasian peptic ulcer patients administered pantoprazole, amoxicillin, and metronidazole.
机译:目的:根除幽门螺杆菌是消化性溃疡患者的重要治疗策略。当前的根除方案包括质子泵抑制剂(PPI)和两种抗生素。 PPI的影响可能取决于它们的代谢以及对消化性溃疡疾病的病理生理重要的其他因素。本研究的目的是评估在使用pan托拉唑,阿莫西林和甲硝唑三联疗法治疗的波兰白种人患者中,CYP2C19,MDR1和IL-1B多态性与幽门螺杆菌根除率的相关性。方法:总共139例幽门螺杆菌感染阳性的消化性溃疡患者接受了三联疗法(pan托拉唑+阿莫西林+甲硝唑)治疗。随后,将患者分为两组(第1组,治疗成功,第2组,治疗后根除失败),并通过PCR-RFLP方法对CYP2C19变异等位基因的存在进行基因分型(* 2,* 3和* 17) ),以及MDR1 3435C> T和IL-1B + 3954C> T多态性。使用HPLC方法测量托拉唑的血清浓度。结果:两组患者之间CYP2C19基因型的频率或分布没有明显差异(即成功根除幽门螺杆菌和治疗失败)。然而,在治疗失败的患者中发现任何CYP2C19 * 2 / * 2基因型缺陷的携带者。同样,发现MDR1和IL-1B基因型与根除幽门螺杆菌的成功或失败显着相关。基因型的单变量和多变量分析未发现基因型与根除幽门螺杆菌之间存在任何显着关联。 top托拉唑浓度差异显着,在等位基因CYP2C19 * 2携带者缺陷患者中最高,而在基因型纯合子CYP2C19 * 17 / * 17活跃的患者中最低。结论:与MDR1和IL-1B基因型相反的CYP2C19基因型可能对使用潘托拉唑治疗的消化性溃疡患者中幽门螺杆菌根除的疗效产生影响,在波兰高加索消化性溃疡患者中使用潘托拉唑,阿莫西林和甲硝唑。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号